Recent News

ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
July 29, 2021
ERYTECH Granted U.S. FDA Fast Track Designation  for E ryaspase in Hypersensitive ALL Fast Track d esignation for eryaspase underscores the need for new treatment options for patients who developed hypersensitivity reactions to pegylated asparaginase Cambridge, MA (U.S.) and Lyon (France), July 29
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference
July 27, 2021
ERYTECH to Participate in the BTIG Virtual Biotechnology Conference Cambridge, MA (U.S.) and Lyon (France) , Ju ly 2 7 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside